Hair Growth Supplements Market to be Worth USD 2,581.1 Million by 2032: Coherent Market Insights
Burlingame, CA, May 23, 2025 (GLOBE NEWSWIRE) — The global hair growth supplements market was valued at approximately USD 940.1 million in 2025, and this figure is projected to reach around USD 2,581.1 million by 2032, expanding at a robust compound annual growth rate (CAGR) of 15.5%. The expansion of the hair growth supplements industry is largely driven by a growing preference for nutraceuticals over pharmaceuticals, due to their perceived higher safety profile. Additionally, rising awareness of the nutritional benefits provided by supplements has contributed to this shift. The increasing incidence of hair loss caused by various conditions, along with a heightened focus on maintaining healthy hair, has further boosted the demand for hair growth supplements.
Request Sample Report @ https://www.coherentmarketinsights.com/insight/request-sample/7714
Global Hair Growth Supplements Market Key Takeaways
According to Coherent Market Insights (CMI), the global hair growth supplements market size is forecast to grow from USD 940.1 Mn in 2025 to USD 2,581.1 Mn by 2032.
Global demand for hair growth supplements will likely increase at a robust CAGR of 15.5% throughout the assessment period.
Based on product type, single ingredient supplements segment is expected to account for more than half of the global hair growth supplements market share in 2025.
By formulation, capsules segment is projected to account for nearly one-fourth of the hair growth supplements market revenue share in 2025.
In terms of functionality, hair regrowth segment is set to hold a prominent market share of more than 1/3 in 2025.
North America is anticipated to dominate the global hair growth supplements industry, accounting for more than one-third of revenue share in 2025.
As per Coherent Market Insights' latest hair growth supplements market analysis, Asia Pacific is expected to experience fastest growth during the assessment period. This can be attributed to growing health and wellness trend and increasing spending on hair supplements like vitamins. Rising emphasis on maintaining healthy hair has also fueled an adoption of hair growth supplements in the region.
Also Read: Hair Loss Treatment Market Size, Share & Trend Analysis Report (2025-2032)
Rising Prevalence of Hair Loss Disorders Propelling Growth
Coherent Market Insights' latest hair growth supplements market research report outlines prominent factors driving industry growth. This includes increasing incidence of hair loss disorders globally.
Hair loss disorders, such as androgenetic alopecia (AGA) and alopecia areata (AA) are becoming more prevalent globally. According to an article published by the American Academy of Dermatology (AAD), alopecia areata affects around 2% of the global population. This high disease burden is expected to boost growth of the hair growth supplements market.
Hair growth supplements are gaining immense traction among individuals with hair loss issues. They have the tendency to help reduce hair fall and support growth of hair follicles. Thus, higher the cases of hair loss, greater will be demand for hair growth supplements.
Side Effects and Availability of Alternative Therapies Limiting Market Growth
The future hair growth supplements market outlook looks optimistic. However, factors like high cost of premium products and availability of alternative treatments are expected to limit market growth to some extent.
Many hair growth supplements come with a heavy price tag. This limits their affordability and accessibility for a larger customer base, especially in low- and high-income regions. Availability of alternative hair loss treatments like PRPs, topical solutions, and hair transplants is also limiting the overall hair growth supplements market demand.
Request a Customized Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-customization/7714
Growing Awareness of Hair Health Creating Growth Prospects for Players
People across the world are becoming increasingly aware of the importance of maintaining healthy hair, mainly due to rising concerns about hair thinning and hair loss. This growing awareness is creating high demand for hair growth supplements.
Modern consumers seek natural and scientifically backed solutions. This is expected to offer promising opportunities for hair growth supplement manufacturers and suppliers during the assessment period.
Increasing geriatric population will also play a key role in boosting the hair growth supplements market growth. Aging often leads to hair thinning, prompting older consumers to seek non-invasive solutions like hair supplements.
Emerging Hair Growth Supplements Market Trends
Evolving beauty trends are acting as a catalyst for the growth of hair growth supplements market. Personal grooming and aesthetics are taking central stage in the modern world. More and more individuals are turning to hair growth supplements as a convenient and affordable way to address thinning hair and baldness.
Social media is having a profound impact on the hair growth supplements industry. Leading wellness brands, celebrities, and influencers are increasingly promoting hair supplements on platforms like TikTok and Instagram. This growing visibility is increasing consumer interest as well as contributing to higher sales of hair growth supplements.
Rising interest in preventive healthcare is significantly boosting hair growth supplements industry. Consumers are opting for hair supplements not only to address hair loss, but also as a proactive measure to maintain healthy hair as well as prevent future damage.
There is also an increasing consumer preference for organic and plant-based hair growth supplements. This will create lucrative growth opportunities for hair growth supplement companies.
Growing interest in personalized haircare is prompting companies to use advanced technologies like AI algorithms to create tailored treatments. For instance, Roots by Genetic Arts offers personalized topical hair growth solutions based on DNA analysis. Increasing popularity of DNA-based hair supplements will likely boost sales growth.
Leading manufacturers of hair growth supplements are constantly innovating to stay ahead of the curve. For instance, they use marine collagen, adaptogens, and other functional ingredients in their products to woo customers. Similarly, they are strengthening their online presence to reach a wider audience.
Another emerging trend in the hair growth supplements industry is the usage of sustainable packaging. Brands like Herbalife Nutrition Ltd. are transitioning toward compostable packaging for their hair wellness supplements.
Also Read: Hair Care Products Market Size, Share & Trend Analysis Report (2025-2032)
Analyst's View
'The global hair growth supplements industry is poised to grow rapidly, owing to increasing incidence of hair loss disorders, growing health and wellness trend, and rising popularity of novel products like softgel based hair growth supplements ,' said senior analyst Ghanshyam Shrivastava.
Current Events and Their Impact on the Hair Growth Supplements Market Event Description and Impact Rising Incidence of Hair Loss Disorders Description: Cases of hair loss disorders are increasing significantly due to factors like changing lifestyles, unhealthy eating habits, and increased stress levels. Impact: More people with hair loss issues will drive demand for hair growth supplements. Rising Health Consciousness and Wellness Trends Description: There is an increased focus on personal well-being and appearance globally. Impact: Rising emphasis on improving physical appearance will likely contribute to increasing hair growth supplements market value. Advancements in Hair Growth Research and Technology Description: Companies are striving to explore new active ingredients and formulations. Impact: Development of more effective hair growth supplements will further boost the target industry.
Competitor Insights
Key companies in hair growth supplements market report: Viviscal
L'Oréal S.A.
Nature's Bounty
Country Life
New Chapter
Hairfinity Advanced Hair Care
Biotin Beauty
Nutrafol
Swisse Wellness
Parapharmacie Parapharmanet
GNC Holdings
Elvanveda
Foshan Dezhong Pharmaceutical
Herbalife Nutrition Ltd.
Tianjin Tongrentang Group
Key Developments
In October 2024, Force Factor collaborated with Nutrition21, LLC to launch Hair Growth Accelerator. The new supplements are designed to support hair health, thickness, and growth.
In October 2024, Nature's Bounty expanded its Women's wellness portfolio with the launch of new products, including Nature's Bounty Hair Growth Gummies, Nature's Bounty Intimacy Booster, and nature's Bounty Healthy pH Balance. These new products are formulated for stimulating hair growth, enhancing sexual health, and maintain vaginal pH balance in women.
Buy this Premium Hair Growth Supplements Research Report | Fast Delivery Available – [130+ Pages] @ https://www.coherentmarketinsights.com/insight/buy-now/7714
Market Segmentation
By Product Type Insights (Revenue, USD Mn, 2020 – 2032) Single Ingredient Supplements
Multi Ingredient Supplements
By Formulation Insights (Revenue, USD Mn, 2020 – 2032) Capsules
Gummies
Tablets
Powders
Softgels
By Functionality Insights (Revenue, USD Mn, 2020 – 2032) Hair Re-growth
Hair Thinning
Hair Fall
Dandruff
By Distribution Channel Insights (Revenue, USD Mn, 2020 – 2032) Offline Hypermarkets/Supermarkets Specialty Stores Convenience Stores Departmental Stores Drug Stores & Pharmacies Health & Wellness Stores
Online
By End User Insights (Revenue, USD Mn, 2020 – 2032)
Regional Insights (Revenue, USD Mn, 2020 – 2032) North America
Latin America Brazil Argentina Mexico Rest of Latin America
Europe Germany U.K. Spain France Italy Russia Rest of Europe
Asia Pacific China India Japan Australia South Korea ASEAN Rest of Asia Pacific
Middle East GCC Countries Israel Rest of Middle East
Africa South Africa North Africa Central Africa
Also Read: Professional Hair Care Market Size, Share & Growth Analysis Report (2025-2032)
Our Trusted Partners:
Worldwide Market Reports, Coherent MI, Stratagem Market Insights
Get Recent News:
https://www.coherentmarketinsights.com/news
About Us:
Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries.
For Latest Update Follow Us:
LinkedIn | Facebook | Twitter
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% Confirmed Response Rate Four of Five Confirmed Responders Remain in Response Including One Ongoing Remission Over 12 Months Robust Expansion, Persistence, and Tumor Infiltration of ALLO-316 Seen with Standard Lymphodepletion, Showcasing Dagger® Technology as a Next-Generation Allogeneic Platform Phase 1 Safety Profile was Manageable; Proactive Diagnostic and Management Strategies Proved Effective in Mitigating IEC-HS While Preserving Efficacy SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annual Meeting. The Phase 1 TRAVERSE trial enrolled patients with advanced or metastatic renal cell RCC. Leveraging the proprietary Dagger® technology to enable robust CAR T cell expansion, it stands as the first and only allogeneic CAR T product to show promise in treating solid tumors. The presentation focused on the Phase 1b expansion cohort from the Phase 1 TRAVERSE study in which patients were treated with a standard regimen of cyclophosphamide and fludarabine followed by a single dose of 80 million AlloCAR T™ cells. 'ALLO-316 is showing clear evidence of targeted antitumor activity in patients who had failed most or all approved therapies for advanced or metastatic renal cell carcinoma,' said Zachary Roberts, M.D., Ph.D., EVP, Research and Development and Chief Medical Officer at Allogene. 'Our proprietary Dagger technology allows the use of a standard cyclophosphamide and fludarabine-based lymphodepletion regimen with a single dose of ALLO-316. Strong CAR T-cell kinetics and extensive infiltration of tumor tissue by CAR T cells are combining to generate deep and durable remissions. These are results that were previously considered out of reach for patients with advanced solid tumors.' 'Patients diagnosed with advanced or metastatic renal cell carcinoma often face a median survival in months after exhausting standard therapies,' said Samer A. Srour, MB ChB, MS, Associate Professor of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center and lead investigator of the TRAVERSE trial. 'These updated results from a larger cohort of patients with confirmed CD70 positive tumors provide compelling evidence that treatment with ALLO-316 can reduce tumor burden, control disease, and in some cases deliver durable responses. These findings underscore the clinical promise of an allogeneic CAR T to address the significant unmet needs in solid tumors and offer hope to patients who have exhausted other options.' In the Phase 1b expansion cohort, 22 patients whose tumors had progressed on multiple prior therapies were treated with lymphodepletion and 20 were treated with ALLO-316. All patients had tumors resistant to immune checkpoint blockers and at least one tyrosine kinase inhibitor (TKI), 82% had ≥2+ prior TKI, and 41% had prior belzutifan. Sixteen of the ALLO-316 treated patients had a high CD70 Tumor Proportion Score (TPS >50%). The Phase 1b expansion cohort evaluated the safety and efficacy of ALLO-316 at DL2 (80M CAR T cells) following a standard FC lymphodepletion regimen (fludarabine (30 mg/m2/day) and cyclophosphamide (500 mg/m2/day) for 3 days). The median time from enrollment to the start of therapy was four days. A single dose of ALLO-316 stabilized or reversed disease progression in the majority of patients. In the 16 patients with CD70 TPS ≥50%, the trial demonstrated a Confirmed Overall Response Rate (ORR) of 31% with 44% achieving a minimum of 30% reduction in tumor burden. Of the five confirmed responders, four maintain ongoing responses, with one in sustained remission for over 12 months. The median duration of response (mDOR) has not yet been reached, indicating the potential for long-term disease control. CD70+ patients Phase 1b(N=20) ORR (confirmed CR or PR per RECIST v1.1), n/N (%) 5/20 (25) CD70 TPS ≥50%CD70 TPS <50% 5/16 (31)0/4 (0) RECIST v1.1, Response Evaluation Criteria in Solid Tumors, version 1.1; TPS, tumor proportion score The safety profile of ALLO-316 was manageable and consistent with lymphodepletion and an active CAR T product. The most frequent Grade ≥3 events were hematologic and there were no treatment-related Grade 5 events. The most common all-grade adverse events were cytokine release syndrome (CRS) (68%; with no grade ≥3), neutropenia (68%), decreased white blood cell count (68%), anemia (59%), and thrombocytopenia (55%). Immune effector cell-associated neurotoxicity syndrome (ICANS) was 18% (with no grade ≥3) and no graft-versus-host disease (GvHD) occurred. Improved recognition of IEC-HS symptoms led to diagnosis in 36% of patients with 2 patients (9%) experiencing a short-term Grade 3 (one) or Grade 4 (one patient) event. Newly implemented diagnostic and management algorithms significantly mitigated IEC-HS, with no associated Grade 5 events. TEAEs ≥20% incidence in Phase 1b, n (%) Phase 1b (N=22a) All Grades Grade ≥3 Neutropenia 15 (68) 15 (68) White blood cell count decreased 15 (68) 15 (68) Anemia 13 (59) 9 (41) Thrombocytopenia 12 (55) 6 (27) Nausea 8 (36) 0 ALT increased 7 (32) 2 (9) Peripheral edema 7 (32) 0 Pyrexia 7 (32) 0 Arthralgia 6 (27) 0 AST increased 6 (27) 2 (9) Fatigue 5 (23) 0 Headache 5 (23) 0 AEs of Special Interest Any Grade Grade ≥3 CRS 15 (68) 0 Infection 10 (45) 8 (36) IEC-HS 8 (36) 2 (9)b ICANS 4 (18) 0 Graft-versus-host disease 0 0 IEC-HS includes the preferred terms immune effector cell-associated HLH-like syndrome and Hemophagocytic lymphohistiocytosis. a Includes 2 patients who received LD but did not receive ALLO-316 b One patient experienced G4 IEC-HS based on GI bleeding with subsequent improvement and 1 patient experienced G3 IEC-HS based on hypotension managed without pressors with subsequent improvement. About ALLO-316 (TRAVERSE)ALLO-316 is an AlloCAR T™ investigational product targeting CD70, which is highly expressed in renal cell carcinoma (RCC). CD70 is also selectively expressed in several cancers, creating the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors. The ongoing Phase 1 TRAVERSE trial is designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell RCC. In October 2024 the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation based on the potential of ALLO-316 to address the unmet need for patients with advanced or metastatic RCC. The FDA previously granted Fast Track Designation (FTD) to ALLO-316 in March 2023. In April 2024, the Company announced an award from the California Institute for Regenerative Medicine (CIRM) to support the ongoing TRAVERSE trial with ALLO-316 in RCC. About Allogene TherapeuticsAllogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of 'off-the-shelf' CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit and follow @AllogeneTx on X and LinkedIn. Cautionary Note on Forward-Looking Statements for Allogene This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. This press release may, in some cases, use terms such as 'develop,' 'potential,' 'expect,' 'can,' 'enable,' 'showing,' 'generate,' 'may,' 'could,' 'designed to,' 'promise,' 'hope,' 'ongoing,' 'indicating,' 'mitigate,' 'evaluate,' 'pioneer,' 'goal' or 'will,' including alternative forms thereof, or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential of ALLO-316 to treat patients with advanced or metastatic RCC or to provide meaningful clinical benefit in patients with advanced RCC; the potential for ALLO-316 to be developed across a variety of both hematologic malignancies and solid tumors and to generate deep and durable remissions; the potential that ALLO-316 can reduce tumor burden, control disease, and deliver durable responses; the design and potential benefits of our Dagger technology; whether the Dagger® technology will become the next-generation allogeneic platform; ALLO-316 and the Dagger technology's ability to enable robust CAR T cell expansion and persistence and tumor infiltration; the potential of ALLO-316 to address the unmet need in solid tumors or offer hope to patients who have exhausted other options; the transformative potential of our AlloCAR T™ in solid tumors; the potential advantages of the RMAT and Fast Track designation; and our ability to deliver cell therapy on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene's expectations and actual results, including, risks and uncertainties related to: the limited nature of our Phase 1 data from our clinical trials and the extent to which such data may or may not be validated in any future clinical trials; the extent to which the Food and Drug Administration disagrees with our clinical or regulatory plans or the import of our clinical results, which could cause future delays to our clinical trials or require additional clinical trials; we may encounter difficulties enrolling patients in our clinical trials; we may not be able to demonstrate the safety and efficacy of our product candidates in our clinical trials, which could prevent or delay regulatory approval and commercialization; RMAT and Fast Track designations may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval and the designations can be revoked if the criteria for eligibility cease to be met; and challenges with manufacturing or optimizing manufacturing of our product candidates. These and other risks are discussed in greater detail in Allogene's filings with the Securities and Exchange Commission (SEC), including without limitation under the 'Risk Factors' heading in its Quarterly Report on Form 10-Q for the year ended March 31, 2025. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. AlloCAR T™ and Dagger® are trademarks of Allogene Therapeutics, Inc. Allogene's investigational AlloCAR T™ oncology products utilize Cellectis technologies. The anti-CD70 AlloCAR T program is licensed exclusively from Cellectis by Allogene and Allogene holds global development and commercial rights to this AlloCAR T™ program. Allogene Media/Investor Contact:Christine CassianoEVP, Chief Corporate Affairs & Brand Strategy while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Business Upturn
4 hours ago
- Business Upturn
StreetLeaf Plants its 10,000th Light in Advance of Hurricane Season
TAMPA, FLORIDA, June 01, 2025 (GLOBE NEWSWIRE) — StreetLeaf , the leading provider of solar-powered streetlight services in the United States, has installed its 10 thousandth solar-powered streetlight, just in time for hurricane season, which begins June 1st. The 10,000th light is part of the Shine On Florida initiative, and indeed marks a significant step in the company's mission to provide cost-effective, hurricane resilient infrastructure options to communities across Florida. Shine on Florida is a call to action for Florida's utility companies, local governments, home builders, municipalities, HOAs and residents to rethink current construction choices, and make Florida a model for climate-resiliency. 'Future proofing communities has been a focus of Streetleaf since our inception but our sense of urgency increased exponentially last year when three back-to-back hurricanes hit our local area,' said Liam Ryan, CEO of StreetLeaf. 'Shine On Florida represents expanding access to lighting solutions that enhance safety, improve quality of life, and reduce environmental impact for this hurricane season, as well as for future generations.' Streetleaf has been partnering with large real estate development companies, who have been an integral part of expanding the use of hurricane resilient streetlights across Florida. Those companies include Metro Development Group, D.R. Horton , and Forestar Group Inc. . Streetleaf is also working with more than 50 HOAs to bring these lights to their communities, including the innovative Babcock Ranch, America's first solar-powered town. Tampa Electric Company has played a critical role in helping integrate solar solutions into infrastructure discussions around the Tampa area, as StreetLeaf works to bridge utility-grade performance with forward-thinking innovation. In Manatee County, StreetLeaf installations are now helping neighborhoods stay illuminated during power outages, offering peace of mind in storm-prone seasons. Additionally, homebuilders like Lennar, Kotler, Homes by WestBay, and MI Homes have become early adopters of solar streetlighting, recognizing its value in offering safer, more sustainable communities to their homebuyers. The newly installed lighting systems feature StreetLeaf's solar panel technology, which captures energy even during cloudy conditions, and has 5-day battery backup. Each unit includes high-efficiency LED bulbs that provide superior illumination while consuming minimal power. The lights are equipped with motion sensors and smart controls that adjust brightness based on time of day and pedestrian activity, further optimizing energy usage. Streetleaf lights are DarkSky approved, ensuring minimal light pollution while maximizing visibility and safety for residents. This aligns with StreetLeaf's commitment to creating environmentally responsible lighting solutions that respect natural ecosystems. By choosing Streetleaf's solar lighting solutions, communities benefit from both cost savings and meaningful environmental impact. Each installation saves counties and HOAs tens of thousands of dollars annually in electricity costs, while eliminating the need for trenching and wiring can reduce upfront infrastructure expenses by hundreds of thousands of dollars. At the same time, Streetleaf helps neighborhoods reduce carbon emissions—just fifty solar streetlights can offset the electricity use of two average households each year. To learn more about the Shine On Florida program, and how Streetleaf is helping Florida communities shine brighter and greener, visit: For more information about StreetLeaf and its services, please visit: . ABOUT STREETLEAFHeadquartered in Tampa, Florida, StreetLeaf specializes in integrating modern, renewable technology into communities through one of the most essential yet often-overlooked features—streetlights. Since its founding in 2019, StreetLeaf has installed over 10,000 lights across the country, from Florida to California, and is rapidly growing to meet the rising demand for resilient, sustainable solutions. StreetLeaf uses high-quality, dependable and proprietary hardware, software, and service to partner with land developers, builders, municipalities, utilities, and HOAs to create safer, greener communities. A carbon-neutral certified company, StreetLeaf is also DarkSky approved, and has offset more than 4 million pounds of CO2 and counting, as a tree is planted for every StreetLeaf light that is installed in the ground. Learn more at
Yahoo
5 hours ago
- Yahoo
Avista issues all-source request for proposals for new energy and capacity resources along with Demand Response
Energy solutions sought to add capacity to Avista's portfolio SPOKANE, Wash., May 30, 2025 (GLOBE NEWSWIRE) -- Avista, through a request for proposal (RFP), is seeking proposals from bidders to add energy and capacity including distributed energy resources, to meet projected resource needs. In addition, Avista is seeking to add a Demand Response program to its portfolio to assist in addressing peak demand. The all-source RFP seeks resources to meet capacity needs for both Washington and Idaho up to 415 MW for winter and 425 MW for summer. As part of this RFP, Avista may bid repowering and/or self-build resources into the RFP. Avista is utilizing an Independent Evaluator for this RFP. Avista's 2025 Electric Integrated Resource Plan filed on December 31, 2024, reflects a need for new electric resources to meet growing customer demand for energy and clean energy requirements of the Clean Energy Transformation Act (CETA) to deliver carbon-neutral electric supply for Washington customers by 2030. 'This RFP represents Avista's efforts to meet its growing customer demand for energy in its service territory while also seeking resources that are clean, affordable and reliable. Avista is dedicated to partnering with innovative providers to deliver resilient energy solutions that support our customers and their evolving energy use.' said Scott Kinney, Avista's Vice President of Energy Resources & Integrated Planning. 'We're proud of our long-standing history of providing reliable power, and these additional resources will help ensure we continue to do so for years to come.' The RFP is open to parties who currently own, propose to develop, or hold rights to resources meeting Avista's requirements for energy and capacity. Bidders must also demonstrate an ability to meet the minimum requirements for eligibility as listed in the RFP. Avista will consider hybrid proposals including combinations of clean energy, capacity and/or storage. Avista will not accept proposals for Renewable Energy Certificates (REC) only. In addition, Avista seeks to acquire at least 5 MW of Demand Response (DR) beginning in 2026. DR programs provide a cost-effective solution to meeting energy demand at peak times and will be evaluated along with supply side resources. RFP responses are due by June 30, 2025. The RFP and bid instructions are available on the Avista website at: About Avista UtilitiesAvista Utilities is involved in the production, transmission and distribution of energy. We provide energy services and electricity to 422,000 customers and natural gas to 383,000 customers in a service territory that covers 30,000 square miles in eastern Washington, northern Idaho and parts of southern and eastern Oregon, with a population of 1.7 million. Avista Utilities is an operating division of Avista Corp. (NYSE: AVA). For more information, please visit To unsubscribe from Avista's news release distribution, send reply message to Contact: Media: Jared Webley, 24/7 Media Access (509) 495-4174
